Article Text

Download PDFPDF
CP-111 Use of a single-tablet HIV regimen in clinical practice after recent inclusion in a hospital formulary
  1. S Ortonobes Roig,
  2. B López García,
  3. A Retamero Delgado,
  4. D Echeverría Esnal,
  5. E Gonzalez Colominas,
  6. D Conde Estevez,
  7. O Ferrandez Quirante,
  8. R Pellicer Voltas,
  9. A Carmona Yelo,
  10. E Salas Sanchez
  1. Hospital de Mar. Parc de Salut Mar., Pharmacy Service, Barcelona, Spain


Background A once-daily single-tablet regimen (STR) containing rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) has been recently approved by the European Medicines Agency (EMA) for the treatment of treatment-naïve HIV patients with a baseline viral load below 100,000 copies/mL. Additionally, it’s prescribed when switching treatment.

Purpose To describe the characteristics of patients starting RPV/FTC/TDF during the first six months of its inclusion in our hospital.

To define reasons to be on RPV/FTC/TDF other than initiating antiretroviral treatment (ART) in treatment-naïve patients.

Materials and methods Retrospective descriptive study including all patients starting or switching to RPV/FTC/TDF between April–September 2013 in a tertiary university hospital. Data collected: demographics (sex, age), starting or switching reasons, previous ART, CD4+ count and HIV viral load at baseline. Data are expressed as median (Q1-Q3).

Results 78 patients initiated RPV/FTC/TDF: 18 (23%) treatment-naïve patients and 60 (77%) pre-treated patients.

Treatment-naïve patients. Men: 16 (88.9%); age: 34.6 (33.8–42.9) years; CD4+ count: 358.0 (304.3–464.5) cell/mcL; HIV-RNA: 44513 (21130–71551) copies/mL. Reasons to start treatment: CD4+ count <500 cell/mcL: 13 (72.2%); patient’s request: 4 (22.2%) and ART restart: 1 (5.6%).

Pre-treated patients. Men: 54 (90.0%); age: 44.9 (38.0–51.2) years; CD4+ count 645.0 (405.8–807.5) cell/mcL; HIV-RNA <50 copies/mL: 48 (89%) patients. Reasons for switching to RPV/FTC/TDF: side effects 48 (80%) patients; drug interactions 3 (5.0%); simplifying to STR 6 (10.0%) and patient’s request 3 (5.0%). Type of side effects: CNS effects 34 (70.8%) patients; gastrointestinal tract dysfunctions 11 (22.9%) and lipid profile abnormalities 3 (6.25%). Previous treatment: non-nucleoside reverse-transcriptase inhibitors (NNRTI) 39 (65.0%) patients and protease inhibitors 21 (35.0%).

Conclusions Only 23% patients starting RPV/FTC/TDF were treatment-naïve, following EMA approval conditions.

Naïve patients were younger, had a lower CD4+ count and higher viral load than pre-treated patients.

Main reason for initiating ART with RPV/FTC/TDF was immunological progression.

Main reasons for switching to RPV/FTC/TDF were side effects such as CNS and gastrointestinal tract dysfunctions.

The most common previous treatment was NNRTI-based ART.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.